Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.83 USD
+0.05 (2.81%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $1.89 +0.06 (3.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RGLS 1.83 +0.05(2.81%)
Will RGLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RGLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGLS
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Other News for RGLS
Optimistic Outlook on Regulus’s RGLS8429 for ADPKD Despite Initial eGFR Concerns
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed on Regulus Amid Promising ADPKD Trial Updates